Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Accounts Payables (2021 - 2026)

Core Scientific has reported Accounts Payables over the past 6 years, most recently at $218.9 million for Q1 2026.

  • Quarterly results put Accounts Payables at $218.9 million for Q1 2026, up 3358.55% from a year ago — trailing twelve months through Mar 2026 was $218.9 million (up 3358.55% YoY), and the annual figure for FY2025 was $126.1 million, up 554.59%.
  • Accounts Payables reached $218.9 million in Q1 2026 per CORZ's latest filing, up from $126.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $218.9 million in Q1 2026 and bottomed at $6.3 million in Q1 2025.
  • Median Accounts Payables over the past 5 years was $45.5 million (2023), compared with a mean of $75.2 million.
  • The largest annual shift saw Accounts Payables surged 18028.55% in 2022 before it tumbled 87.55% in 2024.
  • Over 5 years, Accounts Payables stood at $53.6 million in 2022, then surged by 188.49% to $154.8 million in 2023, then crashed by 87.55% to $19.3 million in 2024, then surged by 554.59% to $126.1 million in 2025, then soared by 73.55% to $218.9 million in 2026.
  • Business Quant data shows Accounts Payables for CORZ at $218.9 million in Q1 2026, $126.1 million in Q4 2025, and $212.2 million in Q3 2025.